0001140361-17-010396.txt : 20170302 0001140361-17-010396.hdr.sgml : 20170302 20170302215812 ACCESSION NUMBER: 0001140361-17-010396 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170228 FILED AS OF DATE: 20170302 DATE AS OF CHANGE: 20170302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kramer Robert CENTRAL INDEX KEY: 0001380956 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 17661404 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 doc1.xml FORM 4 X0306 4 2017-02-28 0 0001367644 Emergent BioSolutions Inc. EBS 0001380956 Kramer Robert 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 0 1 0 0 EVP, Corproate Services Div Common Stock 2016-08-01 4 J 0 1672 0 A 70000 D Common Stock 2016-08-01 4 J 0 1061 0 A 71061 D Common Stock 2016-08-01 4 J 0 1425 0 A 72486 D Common Stock 2017-02-28 4 A 0 8161 0.00 A 80647 D Common Stock 2017-02-28 4 A 0 8162 0.00 A 88809 D Common Stock 2017-02-28 4 F 0 1799 30.63 D 87010 D Employee Stock Option (Right to buy) 25.62 2016-08-01 4 J 0 1672 25.62 A 2021-03-10 Common Stock 1672 19026 D Employee Stock Option (Right to buy) 26.45 2016-08-01 4 J 0 2121 0 A 2022-03-09 Common Stock 2847 24132 D Employee Stock Option (Right to buy) 30.86 2016-08-01 4 J 0 2847 0 A 2023-02-28 Common Stock 2847 32397 D Employee Stock Option (Right to buy) 30.63 2017-02-28 4 A 0 32638 0.00 A 2024-02-27 Common Stock 32638 32638 D In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017. In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018. In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2019 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. Consists of an option granted on 03/01/2016 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. /s/ Eric Burt, Attorney-in-fact 2017-03-02